Citations

Clear

499 citation(s) found for "Tracy, PB".

COMP-05. EVALUATION OF A DEEP LEARNING ARCHITECTURE FOR MRI PREDICTION OF IDH, 1p19q AND TERT IN GLIOMA PATIENTS
Korfiatis, Panagiotis , Buckner, Jan C. , Eckel‐Passow, Jeanette E. , Decker, Paul A. , Jenkins, Robert B. , Wrensch, Margaret , Wiencke, John, Hansen, Helen, Rice, Terri, McCoy, Lucie , Nelson, Sarah J. , Clarke, Jennifer , Taylor, Jennie , Luks, Tracy , Lachance, Daniel Honore , Parney, Ian F. , Decker, Paul A. , Wiencke, John K. , Hansen, Helen M. , Erickson, Bradley J.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi64-vi64

10.1093/neuonc/noy148.260 Get It

Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder
Batchelor, Tracy T. , Thye, Lim Soon, Habermann, Thomas M.

Mayo Clinic

American Society of Clinical Oncology Educational Book | October 29, 2018 | Volume: No volume available | Issue: 36 | Pages: e354-e366

10.1200/edbk_159030 | PMID 27249742 Get It

Primary central nervous system lymphoma, natural killer T-cell lymphoma nasal type, and post-transplant lymphoproliferative disorder are uncommon and complex lymphoproliferative disorders. These disorders present with different risk factors, have complex tumor characteristics, and require unique therapeutic interventions. These diseases require a multidisciplinary complex team approach. This article will update current management approaches and concepts.
Pompe Disease Could Mimic Exam Findings of Amyloidosis: Two Rare Diagnoses Bona Fide
Abeykoon, Jithma P. , Duma, Narjust , Tracy, Jennifer A., Milone, Margherita , Go, Ronald S. , Go, Ronald S

Mayo Clinic

Case Reports in Hematology | October 28, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-4

10.1155/2018/9615834 | PMID 30510819 Get It

A 70-year-old female presented with a three-year history of evolving macroglossia causing dysphagia and dysarthria, with proximal muscle weakness. Given the classic physical finding of macroglossia, the patient underwent extensive evaluation for amyloidosis which proved to be negative apart from a bone marrow biopsy which stained positive for transthyretin without amino acid sequence abnormality, thus giving wild-type transthyretin amyloidosis. Since the wild-type transthyretin amyloidosis could not entirely explain her clinical presentation and evaluation, further studies were conducted in a sequential manner, thus leading to a diagnosis of Pompe disease explaining her presenting signs and symptoms including her macroglossia. Through this fascinating case, we attempt to highlight the approach for the diagnoses of two rare diseases in a patient by emphasizing the importance of having a broad differential diagnosis when presented with findings which may have been thought as pathognomonic for certain diseases.
Is There a Neurologist in the House? A Summary of the Current State of Neurovascular Rotations for Emergency Medicine Residents
Wira, Charles , Nomura, Jason T. , Marcolini, Evie G. , Gentile, Nina , Schreyer, Kraftin E. , Merck, Lisa H. , Siket, Matthew , Greenberg, Karen J. , Zammit, Christopher, Jauch, Edward C. , Bellolio, Fernanda , Group, from the Society for Academic Emergency Medicine Neurological Emergencies Interest, Bellolio, M Fernanda , Madsen, Tracy E. , Chang, Bernard , Greenberg, Karen, Zammit, Christopher G., Group, from the Society for Academic Emergency Medicine Neurological Emergencies Interest

Mayo Clinic

AEM Education and Training | October 6, 2018 | Volume: 2 | Issue: S1 | Pages: No page available

10.1002/aet2.10200 | PMID 30607380 Get It

AbstractObjectivesNeurovascular and neurocritical care emergencies constitute a leading cause of morbidity/mortality. There has been great evolution in this field, including but not limited to extended time‐window therapeutic interventions for acute ischemic stroke. The intent of this article is to evaluate the goals and future direction of clinical rotations in neurovascular and neurocritical care for emergency medicine (EM) residents.MethodsA panel of 13 board‐certified emergency physicians from the Society for Academic Emergency Medicine (SAEM) neurologic emergencies interest group (IG) convened in response to a call for publications—three with fellowship training/board certification in stroke and/or neurocritical care; five with advanced research degrees; three who have been authors on national practice guidelines; and six who have held clinical duties within neurology, neurosurgery, or neurocritical care. A mixed‐methods analysis was performed including a review of the literature, a survey of Council of Emergency Medicine Residency Directors (CORD) residency leaders/faculty and SAEM neuro‐IG members, and a consensus review by this panel of select neurology rotations provided by IG faculty.ResultsThirteen articles for residency neurovascular education were identified: three studies on curriculum, three studies evaluating knowledge, and seven studies evaluating knowledge after an educational intervention. Intervention outcomes included the ability to recognize and manage acute strokes, manage intracerebral hemorrhage, calculate National Institutes of Health Stroke Scale (NIHSS), and interpret images. In the survey sent to CORD residency leaders and neuro‐IG faculty, response was obtained from 48 programs. A total of 52.1% indicated having a required rotation (6.2% general neurology, 2% stroke service, 18.8% neurologic intensive care unit, 2% neurosurgery, 22.9% on a combination of services). The majority of programs with required rotations have a combination rotation (residents rotate through multiple services) and evaluations were positive.ConclusionsVariability exists in the availability of neurovascular/neurocritical care rotations for EM trainees. Dedicated clinical time in neurologic education was beneficial to participants. Given recent advancements in the field, augmentation of EM residency training in this area merits strong consideration.
Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death
Madhavan, Malini , Waks, Jonathan W. , Friedman, Paul A. , Kramer, Daniel B. , Buxton, Alfred E. , Mehta, Ramila A. , Hodge, David O. , Higgins, Angela , Webster, Tracy L., Witt, Chance M. , Cha, Yong‐Mei , Higgins, Angela Y. , Noseworthy, Peter A. , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 17, 2018 | Volume: 9 | Issue: 3 | Pages: No page available

10.1161/circep.115.003283 | PMID 26921377 Get It

Background— The effectiveness of implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden death in patients with an ejection fraction (EF) ≤35% and clinical heart failure is well established. However, outcomes after replacement of the ICD generator in patients with recovery of EF to >35% and no previous therapies are not well characterized. Methods and Results— Between 2001 and 2011, generator replacement was performed at 2 tertiary medical centers in 253 patients (mean age, 68.3±12.7 years; 82% men) who had previously undergone ICD placement for primary prevention but subsequently never received appropriate ICD therapy. EF had recovered to >35% in 72 of 253 (28%) patients at generator replacement. During median (quartiles) follow-up of 3.3 (1.8–5.3) years after generator replacement, 68 of 253 (27%) experienced appropriate ICD therapy. Patients with EF ≤35% were more likely to experience ICD therapy compared with those with EF >35% (12% versus 5% per year; hazard ratio, 3.57; P =0.001). On multivariable analysis, low EF predicted appropriate ICD therapy after generator replacement (hazard ratio, 1.96 [1.35–2.87] per 10% decrement; P =0.001). Death occurred in 25% of patients 5 years after generator replacement. Mortality was similar in patients with EF ≤35% and >35% (7% versus 5% per year; hazard ratio, 1.10; P =0.68). Atrial fibrillation (3.24 [1.63–6.43]; P <0.001) and higher blood urea nitrogen (1.28 [1.14–1.45] per increase of 10 mg/dL; P <0.001) were associated with mortality. Conclusions— Although approximately one fourth of patients with a primary prevention ICD and no previous therapy have EF >35% at the time of generator replacement, these patients continue to be at significant risk for appropriate ICD therapy (5% per year). These data may inform decisions on ICD replacement.
Measurement of Low‐Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry
Lowenstern, Angela , Li, Shuang , Roger, Véronique L. , Robinson, Jennifer G. , Goldberg, Anne C. , Lee, L. Veronica, Louie, Michael J. , Wang, Tracy Y., Návar, Ann Marie , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 16, 2018 | Volume: 7 | Issue: 18 | Pages: No page available

10.1161/jaha.118.009251 | PMID 30371214 Get It

Background The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommended testing low‐density lipoprotein cholesterol ( LDL ‐C) to identify untreated patients with LDL ‐C ≥190 mg/dL, assess lipid‐lowering therapy adherence, and consider nonstatin therapy. We sought to determine whether clinician lipid testing practices were consistent with these guidelines. Methods and Results The PALM (Patient and Provider Assessment of Lipid Management) registry enrolled primary and secondary prevention patients from 140 US cardiology, endocrinology, and primary care offices in 2015 and captured demographic data, lipid treatment history, and the highest LDL ‐C level in the past 2 years. Core laboratory lipid levels were drawn at enrollment. Among 7627 patients, 2787 (36.5%) had no LDL ‐C levels measured in the 2 years before enrollment. Patients without chart‐documented LDL ‐C levels were more often women, nonwhite, uninsured, and non–college graduates (all P <0.01). Patients without prior lipid testing were less likely to receive statin treatment (72.6% versus 76.0%; P =0.0034), a high‐intensity statin (21.5% versus 24.3%; P =0.016), nonstatin lipid‐lowering therapy (24.8% versus 27.3%; P =0.037), and had higher core laboratory LDL ‐C levels at enrollment (median 97 versus 92 mg/dL; P <0.0001) than patients with prior LDL ‐C testing. Of 166 individuals with core laboratory LDL ‐C levels ≥190 mg/dL, 36.1% had no LDL ‐C measurement in the prior 2 years, and 57.2% were not on a statin at the time of enrollment. Conclusions In routine clinical practice, LDL ‐C testing is associated with higher‐intensity lipid‐lowering treatment and lower achieved LDL ‐C levels.
Prognostic significance of t(11;14) expression by FISH in patients with newly diagnosed multiple myeloma in the era of novel therapies.
Vélez, Miguel González , Duma, Narjust , Richter, Joshua R. , Vesole, David H. , Biran, Noa , Parrondo, Ricardo D , Andrews, Tracy , Siegel, David S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e19525-e19525

10.1200/jco.2017.35.15_suppl.e19525 Get It

e19525 Background: Rearrangements of the immunoglobulin heavy chain (IGH) on chromosome 14 are identified by FISH in about 15-20% of patients (pts) with newly diagnosed multiple myeloma (MM). Historically there is variation on the significance on prognosis of these rearrangements: typically, t(4;14), t(14;16) and t(14;20) have high risk (HR), and t(11;14) have standard risk (SR). A recent study (Kaufman et al, Leukemia. 2016 30:633-9) suggests that t(11;14) may confer a worse prognosis We report the prognostic significance of t(11;14) in a single-institution MM cohort. Methods: 87 pts with t(11;14) by CD 138 selected FISH at diagnosis were identified, pts without symptomatic MM were excluded. Cox regression was used for statistical analysis. Progression free survival (PFS), and overall survivals (OS) from diagnosis and post autologous stem cell transplant (ASCT) were analyzed by Kaplan-Meier. Results: Median age at diagnosis was 62 years, 45 pts (52%) were male, and 24 pts (27%) had ISS 3. All pts received either a proteasome inhibitor or an immunomodulatory agent, and 42 (48%) received triplet treatment as induction. Sixty-nine (79%) pts had ASCT, and overall response rate (ORR, partial response or better) post ASCT was 73%. For pts with HR FISH (defined as t(14;16), p53 del, 1q21 gain or 1p del) compared to SR FISH, the ORR post ASCT was 70% vs 77% (p = 0.67). OS from diagnosis was 93% at 3 years, 74% at 4 years and 51% at 5 years. Seven patients (8%) developed plasma cell leukemia, and there was no association between HR and SR FISH (p = 0.66). In multivariate analysis, ISS stage was an independent risk factor for mortality; pts with stage 3 had 7.3 times (CI: 1.16-36.4) and 5.7 times (CI: 1.63-20.0) the risk of mortality than pts with stage 1 and 2. Having an ASCT reduced mortality by 87% (CI: 0.04-0.41). Conclusions: Despite the use of novel therapies the OS at 5 years of our pts with MM was not significantly improved compared to SEER data from 1992-2013 (51% vs 48.5%). Pts with t(11;14) who had ASCT had increased survival compared to those who did not. Our results suggest that t(11;14) may confer a worse prognosis. Further prospective studies evaluating the risk of t(11;14) are warranted.
Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.
Tracy, Sean , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Allmer, Cristine, Macon, William R. , Maurer, Matthew J. , Witzig, Thomas E. , Drake, Matthew T. , Weiner, George J. , Slager, Susan L. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e19067-e19067

10.1200/jco.2016.34.15_suppl.e19067 Get It